Arcturus announced a strategic collaboration with Thermo Fisher to support ARCT-032's Phase 3 development and potential commercialization. Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services, with exclusive commercial manufacturing rights under a future agreement if approved. The deal de-risks scaling and could accelerate the CF program's path to market if Phase 2 proves positive.
ARCT shares fall 56.3% following mixed Phase 2 trial results. Increased lung function observed in some CF participants from ARCT-032. Safety issues reported but deemed unrelated to ARCT-032 therapy. Expanded trial aims to establish efficacy with higher dosage. Next study set for early 2026 may provide clearer results.
